Aggregation System Improves Analysis of Sub-Visible Particles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aggregation System Improves Analysis of Sub-Visible Particles


Pharmaceutical Technology
Volume 38, Issue 5, pp. 2

Shimadzu Scientific Instrument’s Aggregates Sizer Aggregation Analysis System, provides real-time quantitative evaluation of 100 nm to 10 μm subvisible particle (SVP) aggregates. By screening and identifying aggregation-prone proteins in early-stage drug development, manufacturers can save time and reduce costs. The Aggregates Sizer is capable of identifying SVP particles from invisible to visible in a single measurement in microsample quantities as small as 0.4 mL. It also enables quantitative evaluation of the concentration of those aggregates. In addition, the Aggregates Sizer can execute ongoing measurements in intervals as short as one second, allowing users to evaluate rates of change at intermediate stages during the manufacturing process. A batch cell (5 mL sample capacity) enables observation of aggregation processes as samples are mechanically stimulated.

Shimadzu Scientific Instruments

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here